Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR

Apr 2 2011

SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts from the SuperGen PIM kinase inhibitor program. Poster presentations by SuperGen and collaborators will occur on April 3 and 5, 2011 at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.

The posters will present pre-clinical data on the role played by PIM kinases and their pharmacological inhibition in multiple oncology indications. Copies of the posters will be made available for viewing in the Pipeline section of the Company's website www.supergen.com following the respective presentations.

Targeting Pim kinases by SGI-1776 in mantle cell lymphoma

Abstract 586, Poster Section 25, Poster Board 10

Poster Presentation: Sunday, April 3, 1 - 5 pm ET

The serine/threonine kinase Pim-1 promotes drug resistance mediated by the ATP-binding cassette multidrug resistance protein breast cancer resistance protein (BCRP, ABCG2) by stabilizing higher-order BCRP multimers

Abstract 706, Poster Section 29, Poster Board 20

Poster Presentation: Sunday, April 3, 1 - 5 pm ET

PIM kinase inhibition blocks activation of mTOR pathway components and enhances rapamycin-mediated tumor growth inhibition in prostate cancers

Abstract 2915, Poster Section 3, Poster Board 8

Poster Presentation: Tuesday, April 5, 8 am - 12 pm ET